<DOC>
	<DOCNO>NCT01735513</DOCNO>
	<brief_summary>Study hypothesis : Reduction cerebral embolic lesion transcatheter aortic valve implantation use embolic protection device .</brief_summary>
	<brief_title>Intraprocedural Intraaortic Embolic Protection With EmbolX Device Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation</brief_title>
	<detailed_description />
	<criteria>Patients symptomatic severe aortic valve stenosis ( valve area &lt; 0.8 cm2 ) consider candidate TAVI ( TAVR ) logistic European System Cardiac Operative Risk Evaluation score ( EuroSCORE ) ≥15 % surgery deem excessive risk comorbidities risk factor capture score system . Indication TAVI individual patient discuss consensus conference cardiologist cardiac surgeon , patient 's physician 's preference alone consider adequate decision making . The performance TAVI patient approve local authority . All patient agree participate study , write informed consent obtain . Patients exclude TAVI ( TAVR ) presence follow condition : bicuspid aortic valve aortic annulus diameter ≤18 ≥27 mm procelain aorta unprotected leave main disease recent myocardial infarction cerebrovascular event sepsis active endocarditis severe aortic atheroma leave ventricular atrial thrombus active peptic ulcer bleed diathesis hypersensitivity antiplatelet therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>transaortic TAVI TAVR</keyword>
	<keyword>embolic protection device</keyword>
	<keyword>EmbolX</keyword>
	<keyword>efficacy</keyword>
	<keyword>transaortic TAVI</keyword>
	<keyword>reduce incidence new focus restrict diffusion diffusion-weighted MRI</keyword>
</DOC>